and Thanks, everyone. good morning, Scott,
start to year mentioned, performance as the operational categories. another strong a various Scott product strong we of as As well had quarter and segments across
now sharing highlights me quarter. begin commercial segment Let the by from our
plan that I excludes also well QX from excludes the supports the results As versus QX will the biosimilars our on as business comparisons 'XX. to an 'XX the negative basis, financial currency I certain results foreign guidance operational of which making rates divested do, from impact be as which
our well-balanced quarter. and the gross The markets performance. consecutive to our strong driving sales Our XX% on another growth. grew QX quarter developed Europe Italy it the France to net of delivered of low performed close an with expectations, region year prior ahead fifth in our single compared basis, of strong business where digits margin year-over-year of operational making
to brands key QX. Creon continued Our strongly like as in our portfolio Yupelri Dymista, as well and generics perform
performed driven ahead Our North generic in generics America performance [ph], portfolio. also portfolio, Symbicort expectations by better-than-expected injectables our of and our including business
and America products to by Drug We Yupelri. generic product of litigation led year, performance settled was look launching in of forward Breyna, our expect Symbicort. this exclusivity. our including partner have the Delivery, business after North brand the can with We regulatory to and to stronger patent launch expiration several Our new the AstraZeneca develop
to of We eligible anticipate filer the when and issue future final subject launching for becomes determination Breyna exclusivity if another approval. XXX generic FDA's days first-to-file with NDA
For both the remainder America of meet we North and the to exceed year, expectations markets, in of expect Europe. or our developed
this for of solid driven to for mid-single-digit Malaysia, growth expected. performed ARV emerging Middle Korea, better performance. our remain as primarily Lipitor, confident driven East, by of and full deliver region. the performed markets. also performance. Moving Thailand, than this by delivered brand ahead expectations Norvasc, year, well Generics the strong We Viagra to category segment as
Effexor. to our and remain the our buying customer In brand primarily our to expectations like category in Creon, as due confident Japan. outlook year strong for brands behind as slightly JANZ, Amitiza, due including authorized in the performance patterns We generics broad projected of fell the generics, well
better China Greater X% growth performed basis. than year-over-year operational on expected an with
line with policy XX pleased continue We and we confirm expect China. another to to in I'm also self-pay our performance, submissions base strong evolving expectations, that the operational patient navigating retail on we growing while environment. in SFDA have with the under the year focus review of regulatory the as segment
progress its to Tyrvaya that. leveraging in Care. Tyrvaya's Furthermore, direct-to-consumer about part infrastructure, driving recent as in well party QX, to the Tyrvaya our first delivered first highest beyond prescriptions. Viatris. prescriptions including for prescriber as in current confidence together campaign total wins, marketing monthly which its the outlook quarter ahead, coverage Moving remain commercial count of a and provides Eye and from Viatri's as opportunities full-year launching as Medicare we as planned excited launch Tyrvaya March launch-to-date continue
business, execution of successful made have stabilizing believe we 'XX progress strategy our key the significant in base is and our which phase in one We to II of elements the beyond.
expected which our One brand is of to the overall X/X drivers of stabilization effective the primary our our base. forms of management approximately portfolio,
with branded that the various the category our confidence the across the versus new strong segments, for anticipated or launches that in has quarters, performed return $XXX report our Care This plus our our to above to excluding last several business of our business, branded positive has across will of of year gives prior combined performance tremendous at continued impact our pleased the consistently generics geographies. led product expectations Eye second the 'XX, base in half of year. Division, us growth I'm the million
execute all put the position year that I we commitment a strong II. of our stages completing deliver to believe aspects headed We will will solid are another phase expect into phase and in very final the we company
a noteworthy at I provide begin switch focus loss treatment. weight sole our injectable position now three buckets of beginning year. highlighted key for on on We the complex with of the will me updates Let Wegovy, the pipeline our first-to-file with to portfolio a the products. secured we
addition, strength. we achieved we for have confirm that X-milligram In sole the status can also Ozempic first-to-file
have position on strengths previously of we shared a we disclosed, As Ozempic. first-to-file other have the
have Breast for well of our as submitted Anticoagulant, into of we strengthened the as MR-XXX addition, Cancer used this phase NDA clinical our its and an in product, development. In treatment portfolio Abraxane advanced
Dry ANDA once products our indicated for have Glatiramer to Eye filed Within also announce I'm submitted complex first-to-market really pipeline, our for excited Finally, Chronic MR-XXX, NDA another Acetate and which to for FDA is disease. to that novel select FDA. we monthly we
monthly annual monthly have we has compared primary to Phase met our III XX% in reduction reduction of product one GA placebo. ARR a in endpoint GA its in relapse noted, placebo-controlled rate study. a previously demonstrated As
demonstrated this, that priority compared was statistically on scale significant. In addition status score expanded to to the GA monthly, when placebo, relevant once disability clinically
For this II the III forward have with we clinical Meloxicam, FDA trial Phase of to meeting our in we X outcomes, Phase and end initiating look half of our completed year. second May with positive on
for program our enabling to our this track Finally, making on Botox IND progressing remain study IND and year. we our filing and are
Our pipeline as advancing Eye is planned. Care also
are we are along Tyrvaya for year. top-end partner, results August submission with our We, this in in have We China. positive pleased of that now to checking our received China
MR-XXX for Night program Vision progressing Disturbances clinical is Our well. for
We and III-ready Eye IND also MR-XXX Disease. for Dry submitted for Phase are our our
on later which will program, FDA Blepharitis for with aligned initiated Phase we addition, the get our year. study design In III this
hope to stages we study to are executing IND-enabling Keratopathy. for factor treat Neurotrophic growth we all product, progress which an nerve Finally, our MR-XXX, of
I the to I execution hand our I I quarter. over to continues it Sandeep, that want would to be recognize a globe to thank effort, that, colleagues to Sanjeev. around hand like Before over our and been has call delivering With for now the another strong will and team
